Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01866215
Other study ID # University of Lausanne
Secondary ID
Status Completed
Phase N/A
First received May 27, 2013
Last updated June 3, 2014
Start date May 2013
Est. completion date January 2014

Study information

Verified date June 2014
Source University of Lausanne
Contact n/a
Is FDA regulated No
Health authority Switzerland: Ethikkommission
Study type Interventional

Clinical Trial Summary

A high fructose diet increases fasting and post-prandial triglyceride (TG) concentrations in sedentary healthy human subjects.These effects may be secondary to fructose-induced hepatic de novo lipogenesis. Recent evidence indicate that exercise can prevent fructose induced dyslipidemia.This study will evaluate

1. how exercise effects the metabolic fate of oral fructose 1a) when exercise is performed before fructose ingestion 1b) when exercise is performed after fructose ingestion Metabolic effects of exercise will be assessed in healthy male subjects by measuring fructose oxidation (13CO2 production), fructose conversion into glucose (13C glucose concentrations in blood) and hepatic fructose conversion into lipid (13C palmitate-very low density lipoprotein (VLDL) concentrations in blood) after ingestion of 13C-labelled fructose meals

2. how fructose and protein modulate muscle glycogen and intramyocellular lipid repletion after exercise Healthy male subjects will be fed various fructose, glucose, lipid and whey protein meals after a glycogen/intramyocellular lipid depleting exercise. The effects of meals' composition will be assessed after 24 hours by measuring intramyocellular lipids and glycogen using proton-magnetic resonance spectroscopy (MRS).


Recruitment information / eligibility

Status Completed
Enrollment 8
Est. completion date January 2014
Est. primary completion date January 2014
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 40 Years
Eligibility Inclusion Criteria:

- males

- 18-40 years old

- 19 kg/m2>BMI>25kg/m2

- moderate to high usual physical activity

- non-smokers

Exclusion Criteria:

- family history of diabetes mellitus

- ECG anomaly

- any medication

- participation to blood spending or other clinical study in the 3 months before the beginning of this study

- consumption of drugs

- consumption of more than 50g alcool/week

- family history of food intolerance

Study Design

Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science


Related Conditions & MeSH terms


Intervention

Other:
exercise
cycling at 100W during 60 min
Dietary Supplement:
fructose
isocaloric nutrition with fructose, cream and whey protein during the 24 hour following a glycogen/intramyocellular lipid depleting exercise
glucose
isocaloric nutrition with glucose, cream and whey protein during the 24 hour following a glycogen/intramyocellular lipid depleting exercise

Locations

Country Name City State
Switzerland Centre Hospitalier Universitaire Vaudois Lausanne Vaud

Sponsors (3)

Lead Sponsor Collaborator
University of Lausanne Centre Hospitalier Universitaire Vaudois, University of Bern

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Plasma triglyceride measurement of total and VLDL-TG concentrations in study 1 measurements in fasting conditions and every hour from 7:00 am to 4:00 pm (up to 9 hours) No
Primary intramyocellular lipids Measurement by 1H-MRS in muscle vastus lateralis in study 2 after glycogen/intramyocellular lipid depleting exercise and after 24 hour controlled feeding post exercise No
Primary Fructose conversion into lipids Estimated from 13C palmitate-VLDL concentration measured from 7:00 am to 4:00 pm in study 1 (up to 9 hours) No
Secondary Fructose conversion into glucose measurements obtained from plasma 13C glucose concentrations and whole body glucose production measured by 6,6 d2 glucose in study 1) measured between 7:00 am and 4:oo pm (up to 9 hours) No
Secondary intramyocellular glycogen concentrations Measured by 1H-MRS in muscle vastus lateralis in study 2 after glycogen/intramyocellular lipid depleting exercise and after 24 hour controlled feeding post exercise No
Secondary fructose oxidation Calculated from breath 13CO2 production measured from 7:00 am to 4:00 pm in study 1 (up to 9 hours) No
Secondary exogenous lipid oxidation Lipids ingested will be labeled with 13C-triolein, and exogenous lipid oxidation will be measured from breath 13CO2 production measured from 7:00 am to 4:00 pm in study 2 (up to 9 hours) No
See also
  Status Clinical Trial Phase
Completed NCT05483998 - A Study to Evaluate Single and Multiple Doses of TLC-2716 in Healthy Participants Phase 1
Recruiting NCT02417714 - Prospective Evaluation of Next Generation CT Reconstruction (NextGenIR)
Recruiting NCT02235012 - Cognitive Biases Under Ketamine N/A
Completed NCT04418973 - Analysis of Breath Volatile Organic Compounds After Dyspnea Induced in the Healthy Subject. N/A
Completed NCT05088343 - Effect of Hetrombopag on the Pharmacokinetics of Rosuvastatin in Healthy Subjects Phase 1
Not yet recruiting NCT06248801 - Vildagliptin and Metformin Tablets 50/1000 mg Relative to GALVUS MET (50mg/1000 mg) Tablets Phase 1
Terminated NCT04068259 - Single Ascending Dose Study of PBI-4547 in Healthy Subjects Phase 1
Completed NCT03279302 - Trial to Evaluate the PK Profile of Glepaglutide (ZP1848) After a Single IV and After Multiple SC Injections in Healthy Subjects Phase 1
Not yet recruiting NCT06233162 - Febuxostat 80 mg Tablets Relative to Feburic® 80 mg Tablets Phase 1
Recruiting NCT04159844 - Evaluation of the Stiffness and Pressure Applied on the Lower Leg by a New Compression Bandage on Healthy Subjects N/A
Completed NCT06137911 - Evaluation of Safety, Tolerability & Pharmacokinetics of JYP0061 in Healthy Adults. Phase 1
Completed NCT04849286 - Measurement of HTL0016878 in Cerebrospinal Fluid Phase 1
Not yet recruiting NCT06233227 - Dutasteride Soft Capsule 0.5 mg Relative to Avodart 0.5 mg Soft Capsule Phase 1
Completed NCT04096157 - A Study to Assess Isavuconazole Following a Single Dose of Isavuconazonium Sulfate Intravenous Solution Via Nasogastric (NG) Tube Compared to a Single Dose of Oral Capsules Under Fasting Conditions in Healthy Participants Phase 1
Completed NCT01200368 - Trial Evaluating a 13-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants Phase 3
Recruiting NCT05805033 - Peri-Implant Soft Tissue Integration in Humans: Influence of Material N/A
Completed NCT04027803 - Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Single Intravenous Doses of BCD-148 and Soliris® Phase 1
Recruiting NCT03467880 - Multicenter Study of Impulse Oscillometry in Chinese N/A
Completed NCT02903095 - Single Ascending Dose Study of TD-1439 in Healthy Subjects Phase 1
Active, not recruiting NCT02341508 - A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate Lpathomab in Healthy Volunteers Phase 1